Compare Compass Inc. Class A Common Stock (COMP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs IDEXX Laboratories, Inc. — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $39.92B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.7× Compass Inc. Class A Common Stock's market cap, and Compass Inc. Class A Common Stock is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| COMP | IDXX | |
|---|---|---|
Market Cap | $7.05B | $39.92B |
Volume | 15,310,192 | 715,982 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $766.68 |
52-Week Low | $6.68 | $504.70 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $10.47B | $40.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IDEXX Laboratories (IDXX) trades at $513.14, down 0.44% with bearish technical signals despite strong fundamentals. The company demonstrates robust revenue growth, expanding from $3.4B in 2022 to $4.3B in 2025, with net income reaching $1.06B. Recent acquisitions like CoVetAI and diagnostic platform expansions highlight strategic growth initiatives. Technical indicators show oversold conditions with RSI at 26.58, while moving averages signal bearish momentum. Analyst consensus remains optimistic with a $665 price target representing 30% upside potential.
The outlook remains positive given strong earnings beats, expanding profit margins, and strategic acquisitions. However, risks include technical weakness, FX headwinds, and competitive pressures. With 56.5% analyst buy ratings and institutional accumulation, IDXX offers growth potential but requires monitoring of technical support levels near $492-$502 for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
